Featured Publications
Performance characteristics of platelet autoantibody testing for the diagnosis of immune thrombocytopenia using strict clinical criteria
Gabe C, Sirotich E, Li N, Ivetic N, Nazy I, Smith J, Kelton J, Arnold D. Performance characteristics of platelet autoantibody testing for the diagnosis of immune thrombocytopenia using strict clinical criteria. British Journal Of Haematology 2021, 194: 439-443. PMID: 34109621, DOI: 10.1111/bjh.17566.Peer-Reviewed Original ResearchConceptsPlatelet autoantibody testingImmune thrombocytopeniaAutoantibody testingPlatelet autoantibodiesITP patientsDiagnosis of ITPCertain patient subsetsAnti-glycoprotein IIb/IIIaStrict clinical criteriaHigh pretest probabilityAntigen capture assayIIb/IIIaPatient subsetsClinical criteriaPretest probabilityTreatment responsePatientsHigher optical density valuesOptical density valuesThrombocytopeniaAutoantibodiesCapture assayDiagnosisSpecificityTesting
2024
Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support
Radford M, Estcourt L, Sirotich E, Pitre T, Britto J, Watson M, Brunskill S, Fergusson D, Dorée C, Arnold D. Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support. 2024, 2024: cd011305. PMID: 38780066, PMCID: PMC11112982, DOI: 10.1002/14651858.cd011305.pub3.Peer-Reviewed Original ResearchConceptsRed blood cell transfusion strategyHaematopoietic stem cell transplantationLiberal transfusion strategyClinically significant bleedingRestrictive transfusion strategyNon-randomised studiesTransfusion strategyIntensive chemotherapyRandomised controlled trialsRed blood cellsSignificant bleedingAll-cause mortalityLength of hospital admissionAcute leukemiaHaematological malignanciesRisk of clinically significant bleedingHaematopoietic stem cell supportProspective non-randomised studyRisk ratioControlled trialsQuality of lifeStem cell supportStem cell transplantationMalignant haematological disordersCochrane Central Register of Controlled TrialsTreatment of critical bleeding events in patients with immune thrombocytopenia: a protocol for a systematic review and meta-analysis
Sirotich E, Nazaryan H, Chowdhury S, Guyatt G, Agarwal A, Leong R, Wen A, Xu E, Liu B, Pallapothu S, Rathod P, Kwon H, Dookie J, Shafiee A, Charness J, DiRaimo J, Paynter D, Pruitt B, Strachan G, Couban R, Ye Z, Arnold D. Treatment of critical bleeding events in patients with immune thrombocytopenia: a protocol for a systematic review and meta-analysis. Systematic Reviews 2024, 13: 21. PMID: 38184622, PMCID: PMC10770981, DOI: 10.1186/s13643-023-02436-6.Peer-Reviewed Original ResearchConceptsCritical bleedingSystematic reviewEvidence-based treatment protocolsBleeding-related mortalityCochrane Central RegisterEvidence-based recommendationsFull-text screeningBleeding eventsImmune thrombocytopeniaRecommendations AssessmentCentral RegisterControlled TrialsPrimary outcomeSevere thrombocytopeniaPlatelet countEligible studiesPatient outcomesEmergency settingOvid MEDLINEObservational studyTreatment protocolHigh riskMedical emergencyElectronic databasesMethodsLiterature search
2023
Patient perspectives on telemedicine use in rheumatology during the COVID-19 pandemic: survey results from the COVID-19 Global Rheumatology Alliance
Maheswaranathan M, Miller B, Ung N, Sinha R, Harrison C, Egeli B, Degirmenci H, Sirotich E, Liew J, Grainger R, Chock E. Patient perspectives on telemedicine use in rheumatology during the COVID-19 pandemic: survey results from the COVID-19 Global Rheumatology Alliance. Clinical Rheumatology 2023, 43: 543-552. PMID: 37552351, DOI: 10.1007/s10067-023-06717-2.Peer-Reviewed Original ResearchConceptsRheumatic diseasesPerson visitsTelemedicine useMedication changesCOVID-19 pandemicCare of patientsPerspectives of patientsMethodsAn anonymous online surveyPerspectives of telemedicineDisease activityComplete responseMost patientsPatient's perspectiveTelemedicine effectivenessPatientsAnonymous online surveyFree-text responsesSimilar effectivenessDiseaseVisitsTelemedicine usersRheumatologyYounger participantsTelemedicineClinical tasksCharacteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries
Machado P, Schäfer M, Mahil S, Liew J, Gossec L, Dand N, Pfeil A, Strangfeld A, Regierer A, Fautrel B, Alonso C, Saad C, Griffiths C, Lomater C, Miceli-Richard C, Wendling D, Rodriguez D, Wiek D, Mateus E, Sirotich E, Soriano E, Ribeiro F, Omura F, Martins F, Santos H, Dau J, Barker J, Hausmann J, Hyrich K, Gensler L, Silva L, Jacobsohn L, Carmona L, Pinheiro M, Zelaya M, de los Ángeles Severina M, Yates M, Dubreuil M, Gore-Massy M, Romeo N, Haroon N, Sufka P, Grainger R, Hasseli R, Lawson-Tovey S, Bhana S, Pham T, Olofsson T, Bautista-Molano W, Wallace Z, Yiu Z, Yazdany J, Robinson P, Smith C. Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries. Annals Of The Rheumatic Diseases 2023, 82: 698-709. PMID: 36787993, PMCID: PMC10176347, DOI: 10.1136/ard-2022-223499.Peer-Reviewed Original ResearchConceptsSevere COVID-19High disease activityPandemic time periodDisease activityPsoriatic arthritisMale sexAxial spondyloarthritisCOVID-19Multivariable ordinal logistic regressionPoor COVID-19 outcomesOlder ageFuture respiratory pandemicsCOVID-19 severityCOVID-19 outcomesComorbidity burdenGlucocorticoid intakeGlucocorticoid useCancer comorbidityClinical characteristicsCOVID-19 waveRisk stratificationOrdinal logistic regressionReduced oddsSeverity ScaleRespiratory pandemic
2022
Association Between Race/Ethnicity and COVID‐19 Outcomes in Systemic Lupus Erythematosus Patients From the United States: Data From the COVID‐19 Global Rheumatology Alliance
Ugarte‐Gil M, Alarcón G, Seet A, Izadi Z, Montgomery A, Duarte‐García A, Gilbert E, Valenzuela‐Almada M, Wise L, Sparks J, Hsu T, D'Silva K, Patel N, Sirotich E, Liew J, Hausmann J, Sufka P, Grainger R, Bhana S, Wallace Z, Jacobsohn L, Strangfeld A, Mateus E, Hyrich K, Gossec L, Carmona L, Lawson‐Tovey S, Kearsley‐Fleet L, Schaefer M, Machado P, Robinson P, Gianfrancesco M, Yazdany J. Association Between Race/Ethnicity and COVID‐19 Outcomes in Systemic Lupus Erythematosus Patients From the United States: Data From the COVID‐19 Global Rheumatology Alliance. Arthritis Care & Research 2022, 75: 53-60. PMID: 36239292, PMCID: PMC9874592, DOI: 10.1002/acr.25039.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusCOVID-19 outcomesRace/ethnicitySevere COVID-19 outcomesSystemic lupus erythematosus patientsImmunosuppressive drug useLupus erythematosus patientsCOVID-19 severityUS general populationLogistic regression modelsOrdinal logistic regression modelsGlucocorticoid doseDisease activityPandemic time periodSD ageLupus erythematosusPossible confoundersSevere outcomesMultivariable modelHigher oddsGeneral populationPatientsDrug useHealth disparitiesOutcome categoriesFactors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
Yeoh S, Gianfrancesco M, Lawson-Tovey S, Hyrich K, Strangfeld A, Gossec L, Carmona L, Mateus E, Schäfer M, Richez C, Hachulla E, Holmqvist M, Scirè C, Lorenz H, Voll R, Hasseli R, Jayatilleke A, Hsu T, D’Silva K, Pimentel-Quiroz V, del Mercado M, Shinjo S, dos Reis Neto E, da Rocha L, de Oliveira e Silva Montandon A, Pons-Estel G, Ornella S, Exeni M, Velozo E, Jordan P, Sirotich E, Hausmann J, Liew J, Jacobsohn L, Gore-Massy M, Sufka P, Grainger R, Bhana S, Wallace Z, Robinson P, Yazdany J, Machado P. Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. RMD Open 2022, 8: e002508. PMID: 36100295, PMCID: PMC9471207, DOI: 10.1136/rmdopen-2022-002508.Peer-Reviewed Original ResearchConceptsIdiopathic inflammatory myopathiesSevere COVID-19Prednisolone-equivalent doseHigh disease activityDisease activityInflammatory myopathiesMale sexSevere outcomesCOVID-19Multivariable ordinal logistic regressionOlder ageHigher comorbidity burdenLarge registry dataCOVID-19 diagnosisComorbidity burdenRituximab exposureClinical characteristicsRisk stratificationOrdinal logistic regressionRegistry dataHospitalisationSeverity ScaleDemographic dataLogistic regressionPatientsBaseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey
Rider L, Parks C, Wilkerson J, Schiffenbauer A, Kwok R, Farhadi P, Nazir S, Ritter R, Sirotich E, Kennedy K, Larche M, Levine M, Sattui S, Liew J, Harrison C, Moni T, Miller A, Putman M, Hausmann J, Simard J, Sparks J, Miller F, Akpabio A, Alpizar-Rodriguez D, Berenbaum F, Bulina I, Conway R, Singh A, Duff E, Durrant K, Gheita T, Hill C, Howard R, Hoyer B, Hsieh E, Kibbi L, Kilian A, Kim A, Liew D, Lo C, Miller B, Mingolla S, Nudel M, Palmerlee C, Singh J, Singh N, Ugarte-Gil M, Wallace J, Young K, Bhana S, Costello W, Grainger R, Machado P, Robinson P, Sufka P, Wallace Z, Yazdany J, Foster G, Thabane L, Angevare S, Beesley R, Chock E, Degirmenci B, Felix C, Jin S, Mateus E, Peirce A, Sari E, Tseng R, Wang L, Zamora E. Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey. Rheumatology 2022, 61: si143-si150. PMID: 35460240, PMCID: PMC9248066, DOI: 10.1093/rheumatology/keac249.Peer-Reviewed Original ResearchConceptsSystemic rheumatic diseasesCOVID-19 vaccinationRisk factorsDisease flareRheumatic diseasesHigher oddsSARS-CoV-2 severityFlare of diseaseIdiopathic inflammatory myopathiesSystemic lupus erythematosusOxford-AstraZeneca vaccineMultivariable logistic regressionHistory of reactionPotential risk factorsPfizer-BioNTech vaccineLarge international studyImmunosuppressive medicationsInternational studiesVaccines surveyAdverse eventsInflammatory myopathiesPolymyalgia rheumaticaProspective cohortPsoriatic arthritisBaseline factorsSARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry
Liew J, Gianfrancesco M, Harrison C, Izadi Z, Rush S, Lawson-Tovey S, Jacobsohn L, Ja C, Hyrich K, Gossec L, Strangfeld A, Carmona L, Schäfer M, Frãzao-Mateus E, Bulina I, Stafford F, Tufan A, Graver C, Yardımcı G, Zepa J, Al Emadi S, Cook C, Abutiban F, Dey D, Katigbak G, Kaufman L, Kowalski E, Martínez-Martínez M, Patel N, Reyes-Cordero G, Salido E, Smith E, Snow D, Sparks J, Wise L, Bhana S, Gore-Massy M, Grainger R, Hausmann J, Sirotich E, Sufka P, Wallace Z, Machado P, Robinson P, Yazdany J. SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. RMD Open 2022, 8: e002187. PMID: 35387864, PMCID: PMC8987210, DOI: 10.1136/rmdopen-2021-002187.Peer-Reviewed Original ResearchConceptsB-cell depleting therapyBreakthrough infectionsRheumatic diseasesSARS-CoV-2Clinical characteristicsSARS-CoV-2 breakthrough infectionsPre-existing lung diseaseSARS-CoV-2 infectionBreakthrough COVID-19Cell-depleting therapyTwo-dose seriesTime of vaccinationSecond vaccine doseHigh-risk populationMessenger RNA vaccinesCOVID-19 symptomsSingle-dose vaccineCOVID-19Vaccination seriesSystemic glucocorticoidsVaccine doseVaccine effectivenessSecond doseVaccinated individualsLung disease
2021
Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19
Izadi Z, Brenner E, Mahil S, Dand N, Yiu Z, Yates M, Ungaro R, Zhang X, Agrawal M, Colombel J, Gianfrancesco M, Hyrich K, Strangfeld A, Carmona L, Mateus E, Lawson-Tovey S, Klingberg E, Cuomo G, Caprioli M, Cruz-Machado A, Mazeda Pereira A, Hasseli R, Pfeil A, Lorenz H, Hoyer B, Trupin L, Rush S, Katz P, Schmajuk G, Jacobsohn L, Seet A, Al Emadi S, Wise L, Gilbert E, Duarte-García A, Valenzuela-Almada M, Isnardi C, Quintana R, Soriano E, Hsu T, D’Silva K, Sparks J, Patel N, Xavier R, Marques C, Kakehasi A, Flipo R, Claudepierre P, Cantagrel A, Goupille P, Wallace Z, Bhana S, Costello W, Grainger R, Hausmann J, Liew J, Sirotich E, Sufka P, Robinson P, Machado P, Griffiths C, Barker J, Smith C, Yazdany J, Kappelman M, Bachelez H, Capon F, Coker B, De La Cruz C, Mason K, Di Meglio P, Gelfand J, Gisondi P, Iversen L, Jullien D, Lambert J, Langan S, McAteer H, Meynell F, Moorhead L, Naldi L, Puig L, Reynolds N, Spuls P, Torres T, Tsakok T, Vincent A, Warren R, Waweru H, Ng S, Gearry R, Reinisch W, Rahier J, Lewis J, Kaplan G, Steinwurz F, Kissous-Hunt M, Modesto I, Konings M, Dahou B, Gómez G, Roberts K, Baez R, Castro Coello V, Haye Salinas M, Maldonado F, Reyes A, Alle G, Tanten R, Maldonado Ficco H, Nieto R, Gobbi C, Tissera Y, Pisoni C, Paula A, Albiero J, Schmid M, Cosatti M, Gamba M, Leandro C, Cusa M, German N, Bellomio V, Takashima L, Pera M, Cogo K, Gálvez Elkin M, Medina M, Savio V, Rojas Tessel R, Alamino R, Werner M, Ornella S, Casalla L, de la Vega M, Severina M, García M, Gonzalez Lucero L, Romeo C, Moyano S, Barbich T, Bertoli A, Baños A, Petruzzelli S, Matellan C, Conti S, Lazaro M, Rodriguez Gil G, Risueño F, Quaglia M, Scafati J, Cuchiaro N, Rebak J, Pineda S, Calvo M, Picco E, Yanzi J, Maid P, Guaglianone D, Morbiducci J, Porta S, Herscovich N, Velasco Zamora J, Kisluk B, Castaños Menescardi M, Gallo R, Martire M, Maldini C, Goizueta C, de la Vega Fernandez S, Aeschlimann C, Subils G, Rath E, Piette Y, Devinck M, Maeyaert B, Machado Ribeiro F, Euzebio Ribeiro S, Pinheiro M, Ibáñez S, Chassin Trubert A, Dong L, Cajas L, Barešić M, Anić B, Čulo M, Pavelić T, Stranski K, Karanovic B, Vencovsky J, Píchová M, Filkova M, Hamoud H, Vassilopoulos D, Guzman Melgar G, So H, Király M, Vojdanian M, Balbir Gurman A, Abutiban F, Zepa J, Bulina I, Bukauskiene L, Zazueta Montiel B, Castillo Ortiz A, Zamora Tehozol E, Vega Morales D, Cervántes Rosete D, Martín Nares E, Rodriguez Reyna T, Rull Gabayet M, Alpízar Rodríguez D, Irazoque F, Jimenez X, Geurts van Bon L, Zijlstra T, Hoekstra M, Al Adhoubi N, Salim B, Giraldo E, Salinas A, Ugarte Gil M, Nowakowski J, Conway R, Flood R, McCarthy G, Felea I, Filipescu I, Rednic S, Groseanu L, Tamas M, Mlynarikova V, Skamlova M, Zlnay M, Mičeková D, Capova L, Macejova Z, Šteňová E, Raffayova H, Belakova G, Strakova E, Senčarová M, Žlnayová S, Sabová A, Spisakova D, Oetterová M, Lukacova O, Bakosova M, Hocevar A, de la Torre Rubio N, Alegre Sancho J, Corteguera Coro M, Cobeta Garcia J, Torres Martin M, Campos J, Gomez Puerta J, Yardımcı G, Akar S, Icacan O, ÇELİK S, Vasylets V, Yeoh S, Vandevelde C, Dunt S, Leeder J, Macphie E, Salerno R, Graver C, Williams K, O'Reilly S, Devine K, Tyler J, Warner E, Pilcher J, Patel S, Nikiphorou E, Chadwick L, Jones C, Harrison B, Thornton L, O'Kane D, Fusi L, Low A, Horton S, Jatwani S, Baig S, Bajwa H, Berglund V, Dahle A, Dorman W, Hargrove J, Hilton M, Lebedoff N, Leonard S, Morgan J, Pfeifer E, Skemp A, Wilson J, Wolff A, Cepeda E, Todd D, Hare D, Calabrese C, Adams C, Khosroshahi A, Kilian A, White D, Winter M, Fields T, Siegel C, Daver N, Harvey M, Kramer N, Lamore C, Hogarty S, Yeter K, Siddique F, Ban B, Tanner T, Ruderman E, Davis W, Quinet R, Scopelitis E, Toribio K, Webb Detiege T, Zakem J, Abbass K, Kepecs G, Miranda L, Guma M, Haikal A, Mody S, Mueller D, Jayatilleke A, Zell J, Bays A, Dao K, Ezzati F, Parks D, Karp D, Quiceno G. Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. JAMA Network Open 2021, 4: e2129639. PMID: 34661663, PMCID: PMC8524310, DOI: 10.1001/jamanetworkopen.2021.29639.Peer-Reviewed Original ResearchConceptsTNF inhibitor monotherapyCOVID-19-associated hospitalizationTumor necrosis factor inhibitorsNecrosis factor inhibitorsInhibitor monotherapyInflammatory bowel diseaseTNF inhibitorsCOVID-19 outcomesPooled analysisMethotrexate monotherapyImmunomodulatory treatmentMethotrexate therapyClinical characteristicsCohort studyBowel diseaseFactor inhibitorsInflammatory diseasesMAIN OUTCOMEAdverse COVID-19 outcomesCOVID-19Multivariable logistic regression modelMultilevel multivariable logistic regression modelsJAK inhibitor monotherapyKinase inhibitor monotherapyRisk of hospitalizationEarly experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
Sattui SE, Liew JW, Kennedy K, Sirotich E, Putman M, Moni TT, Akpabio A, Alpízar-Rodríguez D, Berenbaum F, Bulina I, Conway R, Singh AD, Duff E, Durrant KL, Gheita TA, Hill CL, Howard RA, Hoyer BF, Hsieh E, Kibbi L, Kilian A, Kim AH, Liew DFL, Lo C, Miller B, Mingolla S, Nudel M, Palmerlee CA, Singh JA, Singh N, Ugarte-Gil MF, Wallace J, Young KJ, Bhana S, Costello W, Grainger R, Machado PM, Robinson PC, Sufka P, Wallace ZS, Yazdany J, Harrison C, Larché M, Levine M, Foster G, Thabane L, Rider LG, Hausmann JS, Simard JF, Sparks JA. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open 2021, 7: e001814. PMID: 34493645, PMCID: PMC8424419, DOI: 10.1136/rmdopen-2021-001814.Peer-Reviewed Original ResearchConceptsDisease-modifying antirheumatic drugsPatient-reported adverse eventsSystemic rheumatic diseasesCOVID-19 vaccinationRheumatic disease flareRheumatic diseasesDisease flareCOVID-19 vaccineAdverse eventsVaccine efficacyMuscle/joint painJanssen/JohnsonTime of vaccinationFever/chillsCommon rheumatic diseasePatient-reported dataOxford/AstraZenecaEarly experienceVaccines surveyAntirheumatic drugsMedication changesJoint painMost patientsPfizer-BioNTechRheumatoid arthritisCOVID-19 in women with rheumatic disease who are pregnant: Data from the COVID-19 Global Rheumatology Alliance
Bermas B, Gianfrancesco M, Tanner H, Seet A, Aguiar M, Al Adhoubi N, Al Emadi S, Cunha B, Flood R, Kusevich D, McCarthy E, Patel N, Ruderman E, Sattui S, Sciascia S, Siddique F, Valenzuela-Almada M, Wise L, Worthing A, Zell J, Bhana S, Costello W, Duarte-Garcia A, Grainger R, Gossec L, Hausmann J, Hyrich K, Lawson-Tovey S, Liew J, Sirotich E, Sparks J, Sufka P, Wallace Z, Machado P, Strangfeld A, Clowse M, Yazdany J, Robinson P. COVID-19 in women with rheumatic disease who are pregnant: Data from the COVID-19 Global Rheumatology Alliance. The Journal Of Rheumatology 2021, 49: 110-114. PMID: 34470798, DOI: 10.3899/jrheum.210480.Peer-Reviewed Original ResearchConceptsRheumatic diseasesPregnant womenPregnancy outcomesObstetric detailsCOVID-19Combination of antimalarialsRheumatic disease diagnosisLopinavir/ritonavirSystemic lupus erythematosusCases of patientsCOVID-19 infectionCoronavirus disease 2019Time of infectionCOVID-19 diagnosisTime of reportAntiphospholipid syndromeInflammatory arthritidesPreterm birthLupus erythematosusMedian ageTerm birthsRheumatoid arthritisSupplemental oxygenArthritis/Medication treatmentAssociation of Race and Ethnicity With COVID‐19 Outcomes in Rheumatic Disease: Data From the COVID‐19 Global Rheumatology Alliance Physician Registry
Gianfrancesco M, Leykina L, Izadi Z, Taylor T, Sparks J, Harrison C, Trupin L, Rush S, Schmajuk G, Katz P, Jacobsohn L, Hsu T, D’Silva K, Serling‐Boyd N, Wallwork R, Todd D, Bhana S, Costello W, Grainger R, Hausmann J, Liew J, Sirotich E, Sufka P, Wallace Z, Machado P, Robinson P, Yazdany J, Alliance T. Association of Race and Ethnicity With COVID‐19 Outcomes in Rheumatic Disease: Data From the COVID‐19 Global Rheumatology Alliance Physician Registry. Arthritis & Rheumatology 2021, 73: 374-380. PMID: 33146001, PMCID: PMC8467766, DOI: 10.1002/art.41567.Peer-Reviewed Original ResearchConceptsRheumatic diseasesGeneral US populationRace/ethnicityVentilatory supportLatinx patientsOdds ratioUS populationCOVID-19Rheumatic disease activityRheumatic disease diagnosisOdds of hospitalizationAfrican American patientsAssociation of raceCOVID-19 outcomesPhysician registryCoronavirus disease 2019COVID-19 hospitalizationMultivariable regression modelsSignificant health disparitiesNeeds of patientsInequitable health outcomesDisease activityHospitalized patientsMedication useWhite patients
2020
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
Gianfrancesco M, Hyrich K, Al-Adely S, Carmona L, Danila M, Gossec L, Izadi Z, Jacobsohn L, Katz P, Lawson-Tovey S, Mateus E, Rush S, Schmajuk G, Simard J, Strangfeld A, Trupin L, Wysham K, Bhana S, Costello W, Grainger R, Hausmann J, Liew J, Sirotich E, Sufka P, Wallace Z, Yazdany J, Machado P, Robinson P. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals Of The Rheumatic Diseases 2020, 79: 859-866. PMID: 32471903, PMCID: PMC7299648, DOI: 10.1136/annrheumdis-2020-217871.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAnti-Inflammatory Agents, Non-SteroidalAntimalarialsAntirheumatic AgentsArthritis, PsoriaticArthritis, RheumatoidBetacoronavirusBiological ProductsCoronavirus InfectionsCOVID-19FemaleGlucocorticoidsHospitalizationHumansJanus Kinase InhibitorsLupus Erythematosus, SystemicMaleMiddle AgedMultivariate AnalysisPandemicsPneumonia, ViralPrednisoneProtective FactorsRegistriesRheumatic DiseasesRisk FactorsSARS-CoV-2Severity of Illness IndexSpondylarthropathiesTumor Necrosis Factor InhibitorsVasculitisYoung AdultConceptsDisease-modifying antirheumatic drugsRheumatic diseasesHospitalisation statusHigher oddsNon-steroidal anti-inflammatory drug useConventional disease-modifying antirheumatic drugsAnti-inflammatory drug useOdds of hospitalisationRheumatic disease diagnosisRheumatic disease medicationsMultivariable-adjusted modelsMultivariable logistic regressionJanus kinase inhibitorCOVID-19 outcomesCOVID-19Prednisone doseAntirheumatic drugsGlucocorticoid exposureInhibitor useAntimalarial useClinical factorsCase seriesSmoking statusReduced oddsDecreased odds